Venture Funding Deals: BioNTech's Big Money Leads January Financings
Executive Summary
BioNTech's $270m Series A round was the biggest start-up financing in January, but sizeable rounds also were raised by Centrexion ($67m), Eureka ($60m) and Pandion ($58m).
You may also be interested in...
Oculis Raises CHF20M To Advance Topical DME Therapy And Turn Swiss
Icelandic clinical stage biotech Oculis closes CHF20M ($20.3m) series B financing to advance development of its Phase IIb topical DME drug candidate, relocate to Switzerland and beef up its management team.
BioNTech Raises $270M Series A Round To Pursue FIPCO Model
German biotech BioNTech has raised $270m in a Series A round as it seeks to broaden its investor base and finance its ambition to be a global, fully integrated pharmaceutical company (FIPCO). In the past nine years the company has secured $950m – including a $180m seed financing in 2008, various research grants ($50m), and upfront and near-term milestone payments from partners ($450m).
Deals in Depth: February 2024
Just one $1bn+ alliance was penned in February, compared to ten in the previous month. In the top alliance by deal value, Neomorph and Novo Nordisk entered into a potential $1.46bn agreement for the discovery, development, and commercialization of molecular glue degraders (MGDs) for cardiometabolic and rare diseases. The collaboration brings together Novo Nordisk's expertise in those disease areas with Neomorph's MGD discovery platform. Neomorph will lead discovery and preclinical activities against selected targets with Novo Nordisk having the right to exclusively pursue further clinical development and commercialization of the compounds.